Project description:This SuperSeries is composed of the following subset Series: GSE18390: Effects of retinoids on estrogen-receptor-positive and -negative breast carcinoma cells: mRNA profiling GSE18628: MicroRNA profiling shows different response to retinoids in estrogen-receptor positive and negative cells Refer to individual Series
Project description:The overall study explores differential sensitivity of estrogen-receptor-positive and -negative breast carcinoma cells to retinoids via gene expression and microRNA profiling in MCF7 and MDA-MB-231 cells. This Series reports results of transcriptional profiling of breast carcinoma cell lines comparing the effects of retinoic acid treatment (6 and 48 hours) on estrogen-receptor-positive (MCF7) and estrogen-receptor-negative (MDA-MB-231) cells.
Project description:The overall study explores differential sensitivity of estrogen-receptor-positive and -negative breast carcinoma cells to retinoids via gene expression and microRNA profiling in MCF7 and MDA-MB-231 cells. This Series reports results of transcriptional profiling of breast carcinoma cell lines comparing the effects of retinoic acid treatment (6 and 48 hours) on estrogen-receptor-positive (MCF7) and estrogen-receptor-negative (MDA-MB-231) cells. mRNA profiling: Retinoic-acid-treated (1microM) vs vehicle-treated cells, two time points (6 and 48h), two cell lines (MCF7 and MDA-MB-231). Two biological replicates for each condition, balanced dye design.
Project description:Goal of this study was to investigate gene expression profiling across different molecular subtypes of breast cancers, such as Estrogen Receptor (ER) positive, HER2 amplified, Triple negative Basal A, Triple negative Basal B.
Project description:This study explores circulating exosomal microRNA expression in patients with estrogen receptor–positive (ER+), HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy. Plasma samples were collected at treatment initiation, and exosomes were isolated for unbiased microRNA expression profiling using microarray technology. Patients were clinically stratified according to endocrine sensitivity at baseline and progression status under CDK4/6 inhibition. The resulting dataset was generated as an exploratory discovery cohort to identify candidate exosomal microRNAs associated with treatment outcome and resistance. These data provide a resource for investigating microRNA programs in the context of CDK4/6 inhibitor response.
